ANA2021 attendees: your registration includes complimentary access to the SIG Series – virtual presentations related to ANA's 18 Special Interest Groups – held throughout November and December. All SIG sessions take place virtually and are scheduled for 11:30 AM – 1:00 PM ET.
Join us this week for the following sessions:
- Cerebrovascular Disease and Interventional Neurology | Monday, December 13
- Although stroke remains the fifth leading cause of death and the number one cause of serious long-term disability in the US, effective acute treatments (thrombolysis and thrombectomy) that reduce death and disability are available and indications keep expanding and evolving. Through case-based presentations and overview of current evidence, faculty will provide emerging applications of interventional treatments. This session with cover important topics, in particular: 1) preclinical and translational thrombolytic therapies; 2) advances in neuroimaging to define the ischemic core and penumbra; and 3) the continuously evolving role of flow diverting stents.
- Movement Disorders | Wednesday, December 15
- This session will focus on the non-neuronal aspects of neurodegeneration in movement disorders. While neuronal loss is the primary focus of most research in neurodegeneration, studies in these diseases demonstrate that neuron-glial interactions may have a key role in the pathogenesis of these diseases. Microglia, astrocytes and oligodendrocytes contribute to the progressive neuropathological abnormalities manifested in these movement disorders through various mechanisms, including neuro-inflammation and excitotoxicity.
- Neuro-Oncology | Friday, December 17
- This session will feature experts discussing treatment strategies for patients with GBM and other CNS malignancies. In this session, we will (1) review the critical barriers to improving therapeutic delivery to invasive tumors, specifically, the blood-brain barrier; (2) explore the role of novel oncolytic virotherapy for treatment of GBM; and (3) discuss the role of intra-arterial delivery of chemotherapy for treatment of CNS malignancies. Advances in therapeutic delivery approaches and an increased understanding of brain tumor patho-biology have the potential to improve therapies for intracranial tumors.
Click a session name above for additional details! All SIG sessions are accessible via ANA OnDEC. To ensure a smooth experience on the day of the event, we strongly encourage you to allow yourself extra time to log into OnDEC.
Click here for the full SIG Series Schedule.
If you have any difficulty, please email info@myana.org.